PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company's lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in Phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7800 that is in Phase II clinical trials for the treatment of spinal muscular atrophy and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy. In addition, the company's development programs include PTC596, which is in Phase I clinical trials to treat chemotherapy resistant cancers. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; and research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.
PTC Therapeutics Inc. (NASDAQ: PTCT) saw its shares jump late Friday morning on positive news on its nonsense mutation Duchenne muscular dystrophy (nmDMD) treatment. The company announced that the National Institute for Health and Care Excellence (NICE) has recommended Translarna (ataluren) for ambulatory patients aged five years and older with nmDMD in connection with a Managed Access Agreement with NHS England. http://247wallst.com/healthcare-business/2016/04/15/is-ptc-therapeutics-on-the-road-to-recovery/
Breaking over $10! PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH PLAINFIELD, N.J., Sept. 12, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on September 8, 2016 it approved non-statutory stock options to purchase an aggregate of 22,900 shares of its common stock to eleven new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new hires' employment compensation.
Getting slammed this mornin -30% back below $10 now PTC Therapeutics announced today that at the end of last week, the Office of Drug Evaluation I (ODE-I) of the U.S. Food and Drug Administration (FDA) denied the company's first appeal of the refuse to file letter issued by the FDA's Division of Neurological Products (DNP) on February 22, 2016 regarding PTC's New Drug Application (NDA) for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).
PTC Therapeutics Duchenne Drug Wins Extended European Approval https://www.thestreet.com/story/138...european-approval.html?puc=yahoo&cm_ven=YAHOO
Down 16% pre-market on negative phase 3 results PTC Therapeutics (PTCT) Says Phase 3 Trial of Ataluren in nmCF Didn't Achieve Endpoints Source: https://www.streetinsider.com/Corpo...in+nmCF+Didnt+Achieve+Endpoints/12619948.html
